Sept 21 (Reuters) – ADARx Pharmaceuticals is targeting a valuation of up to $1.74 billion in its US initial public offering, the company developing RNA drugs said on Monday. The company is aiming to
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Wall St set for higher open as AI stocks rise, oil slides
By Johann M Cherian and Tharuniyaa Lakshmi Sept 21 (Reuters) - The main US stock…
Swiss captain Xhaka sidelined over fake COVID certificate
VIDEO SHOWS: FILE FOOTAGE OF SWITZERLAND MIDFIELDER GRANIT XHAKA SHOWS: VANCOUVER, CANADA (JULY 5, 2026)…
Al Qaeda-linked militants kill more than 100 Malian soldiers in attack this month, sources say
* Attacks in central Mali add pressure on military * Airport in Sevare faces six…
